

PROVIDER MEMO

To: Santa Clara Family Health Plan Providers
From: Utilization Management
Date: December 31, 2019
Subject: Updated 2020 Prior Authorization Grid

Dear Providers,

Santa Clara Family Health Plan (SCFHP) has made some changes to our prior authorization requirements, effective for dates of service on or after January 1, 2020. Attached to this memo are two documents, the **2020 Medical Services Prior Authorization Grid** and the **2020 Medical Benefit Drug Prior Authorization Grid**, indicating services and drugs that require prior authorization for all SCFHP members. Podiatric information to follow supersedes details provided in a December 19, 2019 communication.

The following is a summary of prior authorization changes effective January 1, 2020:

- Added:
 - Requests over the benefit limit
 - Zolgensma (onasemnogene abeparvovec-xioi)
 - Xembify (IV immune globulin)

- Removed:
 - Intensity Modulated Radiation Therapy (IMRT)
 - Fulphila (pegfilgrastim-jmdb)
 - Podiatric services provided in a nursing or skilled nursing facility

For the full list, please see the attached 2020 prior authorization grids. This information is also available on the SCFHP Provider Forms & Documents webpage, www.scfhp.com/for-providers/forms.

If you have any questions regarding this information, please contact the SCFHP Utilization Management department at 408-874-1821.

Thank you for your continued partnership in providing care to SCFHP members.



Medical Covered Services Prior Authorization Grid

This Prior Authorization Grid contains services that require prior authorization only and is not intended to be a comprehensive list of covered services. Providers should refer to the appropriate Evidence of Coverage (EOC), available online at www.scfhp.com, for a complete list of covered services.

Santa Clara Family Health Plan (SCFHP) Utilization Management Department:

Telephone: 1-408-874-1821

Prior Authorization Request Submission Fax Lines: 1-408-874-1957 or 1-408-376-3548

When faxing a request to SCFHP, please:

1. Use the SCFHP Prior Authorization Request – Medical Services Form found at www.scfhp.com
2. Attach pertinent medical records, treatment plans, test results and evidence of conservative treatment to support medical necessity.

Other Contact Information:

SCFHP Automated Eligibility: 1-800-720-3455

SCFHP Customer Service:

Medi-Cal: 1-800-260-2055

Cal MediConnect: 1-877-723-4795

For Non-Emergency Medical Transportation (NEMT) & Non-Medical Transportation (NMT) contact SCFHP Customer Service

Benefits Authorized by Vendors:

Dental Services

Denti-Cal: 1-800-322-6384

Vision Services

Vision Service Plan (VSP): 1-844-613-4779

| Category of Service | Services Requiring Prior Authorization | |
|--|---|---|
| Behavioral Health Treatment | All Behavioral Health Treatment Services for members age 21 years and under with behavioral conditions that may or may not include autism spectrum | |
| Durable Medical Equipment (DME) <i>*Benefit and frequency limits apply. Refer to CMS, Noridian, and/or Medi-Cal Provider Manual</i> | Cal MediConnect | Medi-Cal |
| | <ul style="list-style-type: none"> • Custom made items • Any other DME or medical supply exceeding \$1000 • Prosthetics & customized orthotics exceeding \$1000 • Hearing aids and repairs • Other specialty devices • Requests over the benefit limit | <ul style="list-style-type: none"> • CPAP and BIPAP • Enteral formula and supplies • Hospital bed and mattress • Power wheelchairs, scooters, manual wheelchairs except standard adult and pediatric, and motorized wheelchairs and accessories • Respiratory: Oxygen, BIPAP, CPAP, ventilators • Prosthetics & customized orthotics except off-the-shelf covered items • Hearing aids and repairs • Other specialty devices • Requests over the benefit limit |
| Experimental Procedure | <ul style="list-style-type: none"> • Experimental procedures • Investigational procedures • New technologies | |
| Home Health | <ul style="list-style-type: none"> • All home health services • Home IV infusion services | |
| Inpatient Admissions | <ul style="list-style-type: none"> • All elective medical and surgical inpatient admissions to: <ul style="list-style-type: none"> • Acute hospital • Long Term Acute Care (LTAC) • All admissions for: <ul style="list-style-type: none"> • Acute inpatient psychiatric • Partial hospital psychiatric treatment • Substance use disorder including detoxification • Rehabilitation and therapy services: <ul style="list-style-type: none"> • Acute rehabilitation facilities • Skilled Nursing Facilities (SNF) | |
| Long-Term Services and Supports (LTSS) | <ul style="list-style-type: none"> • Community-Based Adult Services (CBAS) • Long-Term Care (LTC) | |

| Category of Service | Services Requiring Prior Authorization |
|------------------------------------|---|
| Medications | <ul style="list-style-type: none"> Refer to the 2020 Medical Benefit Drug Prior Authorization Grid Physician administered drugs in the doctor's office or in an outpatient setting |
| Non-Contracted Providers | All non-urgent/non-emergent services provided by non-contracted providers |
| Organ Transplant | All organ transplants |
| Outpatient Services and Procedures | <ul style="list-style-type: none"> Abdominoplasty/Panniculectomy Bariatric surgery Breast reduction and augmentation surgery Cataract surgery Cochlear auditory implant Dental surgery, jaw surgery and orthognathic procedures Dermatology: <ul style="list-style-type: none"> Laser treatment Skin injections Implants All types of endoscopy except colonoscopy Gender reassignment surgery Genetic testing and counseling Hyperbaric oxygen therapy Intensive Outpatient Palliative Care (IOPC) Neuro and spinal cord stimulators Outpatient diagnostic imaging: <ul style="list-style-type: none"> Magnetic Resonance Imaging (MRI) Magnetic Resonance Angiography (MRA) Nuclear cardiology procedures Single-Photon Emission Computerized Tomography (SPECT) Positron-Emission Tomography (PET/PET-CT) Outpatient therapies <ul style="list-style-type: none"> Occupational Therapy (OT) Physical Therapy (PT) Speech Therapy (ST) All plastic surgery and reconstructive procedures Podiatric surgeries Radiation therapy: <ul style="list-style-type: none"> Proton beam therapy Stereotactic Radiation Treatment (SBRT) Sleep studies Spinal procedures except epidural injections Surgery for Obstructive Sleep Apnea (OSA) Temporomandibular Disorder (TMJ) treatment |



| Category of Service | Services Requiring Prior Authorization |
|---------------------|--|
| | <ul style="list-style-type: none">• Transplant-related services prior to surgery except cornea transplant• Unclassified procedures• Varicose vein treatment |
| Transportation | Non-Emergency Medical Transportation (NEMT) for ground and air except ground transportation from facility to facility and hospital to home. |

The following drugs require prior authorization for all Santa Clara Family Health Plan members. Additional required actions, restrictions, or limits on use are indicated in the right column.

Abbreviations used in this document include:

ST: Step Therapy

PA: Prior Authorization

| Brand | Generic | Necessary Actions, Restrictions, or Limits on Use |
|--|------------------------------------|---|
| ANTIEMETICS (ASSOCIATED WITH CANCER CHEMOTHERAPY) | | |
| Cinvanti | Aprepitant | PA |
| Emend IV | Fosaprepitant | PA |
| Aloxi | Palonosetron | PA |
| ANTIHEMOPHILIC AGENTS | | |
| Hemlibra | Emicizumab-kxwh | PA |
| CAR-T CELL IMMUNOTHERAPY | | |
| Yescarta | Axicabtagene ciloleucel | PA |
| Kymriah | Tisagenlecleucel | PA |
| ERYTHROPOIESIS STIMULATING AGENTS | | |
| Aranesp | Darbepoetin alfa | PA, ST: Retacrit |
| Epogen, Procrit | Epoetin alfa | PA, ST: Retacrit |
| Retacrit | Epoetin alfa-epbx | PA |
| COLONY STIMULATING FACTORS | | |
| Neupogen | Filgrastim | PA, ST: Zarxio or Nivestym |
| Neulasta, Neulasta Onpro | Pegfilgrastim | PA, ST: Fulphila or Udenyca |
| Granix | Tbo-filgrastim | PA, ST: Zarxio or Nivestym |
| Leukine | Sargramostim | PA, ST: Zarxio, Nivestym, Fulphila, or Udenyca |
| GAUCHER DISEASE | | |
| Cerezyme | Imiglucerase | PA |
| ElELYso | Taliglucerase alfa | PA |
| Vpriv | Velaglucerase alfa | PA |
| HEREDITARY ANGIOEDEMA | | |
| Berinert, Cinryze, Haegarda | C1 esterase inhibitor, human | PA |
| Ruconest | C1 esterase inhibitor, recombinant | PA |
| Kalbitor | Ecallantide | PA |
| Firazyr | Icatibant | PA |
| Takhzyro | Lanadelumab-flyo | PA |

| Brand | Generic | Necessary Actions, Restrictions, or Limits on Use |
|--|--|---|
| IV IMMUNOGLOBULIN (IVIG) | | |
| Bivigam, Carimune NF, Cuvitru, Flebogamma DIF, Gamastan, Gamastan S/D, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hyqvia, Octagam, Panzyga, Privigen, Xembify | Immune globulin, Immune globulin lyophilized, Immune globulin non- lyophilized | PA |
| MULTIPLE SCLEROSIS | | |
| Tysabri | Natalizumab | PA |
| Ocrevus | Ocrelizumab | PA |
| NEUROMUSCULAR BLOCKING AGENTS | | |
| Dysport | AbobotulinumtoxinA | PA |
| Xeomin | IncobotulinumtoxinA | PA |
| Botox | OnabotulinumtoxinA | PA |
| Myobloc | RimabotulinumtoxinB | PA |
| OPHTHALMIC AGENTS | | |
| Eylea | Aflibercept | PA |
| Lucentis | Ranibizumab | PA |
| Luxturna | Voretigene neparvovec-rzyl | PA |
| OSTEOPOROSIS OR BONE MODIFIERS | | |
| Prolia, Xgeva | Denosumab | PA |
| Boniva | Ibandronate sodium (IV) | PA |
| Aredia | Pamidronate disodium | PA |
| Reclast, Zometa | Zoledronic acid | PA |
| PULMONARY HYPERTENSION | | |
| Flolan, Veletri | Epoprostenol | PA |
| Remodulin | Treprostinil (injection) | PA |
| RESPIRATORY | | |
| Aralast NP, Glassia, Prolastin-C, Zemaira | α-1 Proteinase inhibitor | PA |
| Nucala | Mepolizumab | PA |
| Xolair | Omalizumab | PA |
| Synagis | Palivizumab | PA |
| Cinqair | Reslizumab | PA |

| Brand | Generic | Necessary Actions, Restrictions, or Limits on Use |
|---|--|---|
| RHEUMATOLOGY/IMMUNOSUPPRESSANTS | | |
| Orencia | Abatacept | PA |
| Humira, Cyltezo, Amjevita, Hyrimoz, Hadlima | Adalimumab, Adalimumab-adbm, Adalimumab-atto, Adalimumab-adaz, Adalimumab-bwwd | Pharmacy Benefit Only |
| Cimzia | Certolizumab pegol | Pharmacy Benefit Only |
| Enbrel, Erelzi | Etanercept, Etanercept-szss | Pharmacy Benefit Only |
| Simponi Aria | Golimumab | PA |
| Tremfya | Guselkumab | PA |
| Remicade | Infliximab | PA, ST: Inflectra, Renflexis, or Ixifi |
| Inflectra, Renflexis, Ixifi | Infliximab-dyyb, Infliximab-abda, Infliximab-qbtx | PA |
| Taltz | Ixekizumab | Pharmacy Benefit Only |
| Rituxan, Rituxan Hycela | Rituximab, Rituximab/hyaluronidase | PA, ST: Truxima or Ruxience |
| Truxima, Ruxience | Rituximab-abbs, Rituximab-pvvr | PA |
| Actemra | Tocilizumab IV | PA |
| Stelara | Ustekinumab IV | PA |
| Entyvio | Vedolizumab | PA |
| MISCELLANEOUS | | |
| Exondys 51 | Eteplirsen | PA |
| Spinraza | Nusinersen | PA |
| Onpattro | Patisiran | PA |
| Krystexxa | Pegloticase | PA |
| Nplate | Romiplostim | PA |
| Radicava | Edaravone | PA |
| Zolgensma | Onasemnogene abeparvovec-xioi | PA |
| UNCLASSIFIED | | |
| Unclassified drugs and biologics | | PA |